The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention‐Deficit/Hyperactivity Disorder

Ole Jakob Storebø, Erlend Faltinsen, Morris Zwi, Erik Simonsen, Christian Gluud

Clinical Pharmacology & Therapeutics · 2018 · 26 citations · 2 references

Concepts

Abstract

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

References

2